D.C. Lung Cancer Conference 2023

D.C. Lung Cancer Conference 2023 is organized by MedStar Health and will be held on Oct 07, 2023 at The Mayflower Hotel, Autograph Collection, Washington, Dist of Col, United States of America.

Overview:
This one-day conference will provide a comprehensive, multidisciplinary update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past year, there have been major shifts in our understanding of this highly lethal disease. We have seen high-impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High-impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide an important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results, and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early-stage and locally advanced lung cancer to include discussions on modern bronchoscopy, proton beam radiation, minimally invasive surgery, and both neoadjuvant and adjuvant systemic therapy. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over the use of emerging biomarkers to guide treatment of advanced NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review.

Objectives:
After completing this activity, the participant will be able to:

• Identify the benefit of CT screening for lung cancer.
• List the currently approved targeted options for patients with MET exon 14 mutant lung cancer.
• Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
• Describe the role of the patient advocate in clinical research.
• Discuss the current application of liquid biopsy (or ctDNA analysis).
• Debate the use of targeted therapy for patients with resected EGFR mutant non-small cell lung cancer.
• Explain the toxicity associated with targeted therapy given after immunotherapy in EGFR mutant non-small cell lung cancer.
• Explain the approved adjuvant and neoadjuvant treatment options for resectable, driver-negative non-small cell lung cancer.
• Explain the significance and use of patient-centered communications on the patient and family experience.
• Summarize strategies for navigating conversations with patients and families.
• Discuss standard targeted agents in use for patients with ALK-positive non-small cell lung cancer.
• Discuss the management of immune-mediated toxicities.
• Describe the benefit of immunotherapy in the treatment of small-cell lung cancer.
• Describe the approved use of tumor-treating fields.
• Identify nursing strategies for early detection of immune-mediated toxicities.
• Recognize unique toxicities associated with targeted agents used in NSCLC.
• Describe current standard care for advanced mesothelioma.
• Discuss standard initial therapy for advanced small cell lung cancer (SCLC).
• Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with lung cancer.
•  Integrate a team-based approach in the care of patients with lung cancer.